17:46 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Scynexis planning Phase III program for vulvovaginal candidiasis candidate

Scynexis Inc. (NASDAQ:SCYX) said all five dose regimens of oral SCY-078 showed "meaningful clinical and mycological activity" in the double-blind, U.S. Phase IIb DOVE trial in 186 patients with moderate to severe acute vulvovaginal candidiasis....
23:50 , Mar 6, 2017 |  BC Week In Review  |  Clinical News

IV SCY-078 regulatory update

FDA placed a clinical hold on IV SCY-078 from Scynexis until the agency completes a review of clinical and preclinical data for the product. The decision was based on a review of 3 mild to...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

SCY-078: Additional Phase II data

Additional data from 14 patients with invasive candidiasis who were initially treated with IV echinocandin in an open-label, international Phase II trial showed that there were no reports of mycological failure in patients receiving 750...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

SCY-078: Phase II data

Pooled data from 96 adult patients with vulvovaginal candidiasis in a single-blind, Dominican Phase II trial showed that oral SCY-078 improved clinical cure rate at the TOC visit at day 24 (78.1% vs. 65.6%) and...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

SCY-078: Interim Phase II data

Interim data from 22 evaluable patients with invasive candidiasis who were initially treated with IV echinocandin in an open-label, international Phase II trial showed that oral SCY-078 was well tolerated. Scynexis said the optimal dose...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Clinical News

IV SCY-078 regulatory update

FDA granted Fast Track and Qualified Infectious Disease Product (QIDP) designations to IV SCY-078 to treat invasive candidiasis and invasive aspergillosis. The product is in Phase I testing. In 2014, FDA granted the same designations...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

SCY-078: Phase II started

Scynexis began an international Phase II trial to compare once-daily oral SCY-078 vs. oral fluconazole in at least 90 patients who received initial therapy with IV echinocandin. Patients in the SCY-078 arms will receive a...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

IV SCY-078: Phase I started

Scynexis began a placebo-controlled Phase I trial to evaluate single ascending doses of IV SCY-078 in about 36 healthy volunteers. Scynexis Inc. (NASDAQ:SCYX), Research Triangle Park, N.C.   Product: IV SCY-078   Business: Infectious  ...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

Scynexis, Accuratus Lab Services deal

Accuratus’ Avista Pharma Solutions subsidiary acquired Scynexis’ CRO, animal health and development services businesses for $3.9 million. The deal includes a screening platform and technology, process chemistry and analytical services. Scynexis said it will focus...
07:00 , Jun 2, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...